Cancer Biotherapy and Radiopharmaceuticals · 2003 · 48 citations · 13 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingRadiation DosimetryTherapeutic Nuclear MedicineDose CalculationMedical ImagingNuclear Medicine ImagingPatient-specific DosimetryPhantom DosimetryThree-dimensional Dose Distribution3D Dose MappingPatient-specific Dose CalculationPatient-specific Dose EstimationThermoluminescent DetectorsThermoluminescent DosimetersThree-dimensional Dose CalculationVoxel DosimetryVoxel Phantom Dosimetry
A computer program, VoxelDose, was developed to calculate patient specific 3-D-dose maps at the voxel level. The 3-D dose map is derived in three steps: (i) The SPECT acquisitions are reconstructed using a filtered back projection method, with correction for attenuation and scatter; (ii) the 3-D cumulated activity map is generated by integrating the SPECT data; and (iii) a 3-D dose map is computed by convolution (using the Fourier Transform) of the cumulated activity map and corresponding MIRD voxel S values. To validate the VoxelDose software, a Liqui-Phil abdominal phantom with four simulated organ inserts and one spherical tumor (radius 4.2 cm) was filled with known activity concentrations of 111In. Four cylindrical calibration tubes (from 3.7 to 102 kBq/mL) were placed on the phantom. Thermoluminescent mini-dosimeters (mini-TLDs) were positioned on the surface of the organ inserts. Percent differences between the known and measured activity concentrations were determined to be 12.1 (tumor), 1.8 (spleen), 1.4, 8.1 (right and left kidneys), and 38.2% (liver), leading to percent differences between the calculated and TLD measured doses of 41, 16, 3, 5, and 62%. Large differences between the measured and calculated dose in the tumor and the liver may be attributed to several reasons, such as the difficulty in precisely associating the position of the TLD to a voxel and limits of the quantification method (mainly the scatter correction and partial volume effect). Further investigations should be performed to better understand the impact of each effect on the results and to improve absolute quantification. For all other organs, activity concentration measurements and dose calculations agree well with the known activity concentrations.
13
Gregory A. Wiseman, Christine A. White, Michael Stabin et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 234 citations
Medicine, Oncology, Pharmacotherapy +15
Marion de Jong, Willem H. Bakker, Eric P. Krenning et al. · European Journal of Nuclear Medicine and Molecular Imaging · 1997 · 212 citations